Loading…
Reported covered position: Senator Kennedy intern (1999-2000)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Elijah E. Cummings Lower Drug Costs Now Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Supply Chain,Drug Pricing (H.R.3, SFC bill PDPRA), Medicare Part D Redesign, Renal Care Policy, Mental Health Policy Issues
Elijah E. Cummings Lower Drug Costs Now Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Mental Health Policy, Renal Care Policy, Drug Pricing (H.R.3, SFC bill PDPRA, Drug Pricing (H.R.3, SFC bill PDPRA), Medicare Part D Redesign
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2020 · fourth_quarter · Q4
Kidney Health, Mental Health
Medicare Part D Redesign, Supply Chain, Drug Pricing, Digital Health
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
Elijah E. Cummings Lower Drug Costs Now Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Medicare Part D Redesign, Drug Pricing (H.R.3, SFC bill PDPRA)
Elijah E. Cummings Lower Drug Costs Now Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Medicare Part D Redesign, Drug Pricing (H.R.3, SFC bill PDPRA)
EMPLEO Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Part D Rule - Medicare's 6 Protected Classes
EMPLEO Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Medicare's 6 Protected Classes
Overdose Prevention and Patient Safety Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
PKD (Polycystic Kidney Disease) Awareness, Opioid Package, S. 1850 (Protecting Jessica Grubb's Legacy Act), H.R. 3545 (Overdose Prevention and Patient Safety Act) and Veteran Affairs Issues
Overdose Prevention and Patient Safety Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
ADPKD (Autosomal dominant polycystic kidney disease); H.R.6082 OVERDOSE PREVENTION AND PATIENT SAFETY ACT - 42 CFR Part 2 - Federal confidentiality law and regulations; Health Care issuses as it relates to TBI (Traumatic Brain Injuries) Clinical Trials
Protecting Jessica Grubb's Legacy Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
PKD (Polycystic Kidney Disease) Awareness, Opioid Package, S. 1850 (Protecting Jessica Grubb's Legacy Act), H.R. 3545 (Overdose Prevention and Patient Safety Act) and Veteran Affairs Issues
2020 · third_quarter · Q3
Medicare Part D Redesign, Kidney Health, Digital Health
Kidney Health, Mental Health
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2020 · second_quarter · Q2
Kidney Health, Mental Health
Supply Chain,Drug Pricing (H.R.3, SFC bill PDPRA), Medicare Part D Redesign, Renal Care Policy, Mental Health Policy Issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2020 · first_quarter · Q1
Mental Health Policy, Renal Care Policy, Drug Pricing (H.R.3, SFC bill PDPRA, Drug Pricing (H.R.3, SFC bill PDPRA), Medicare Part D Redesign
42 CFR Part 2, Kidney Health, Mental Health
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2019 · fourth_quarter · Q4
42 CFR Part 2, Kidney Disease, Mental Health
Medicare Part D Redesign, Drug Pricing (H.R.3, SFC bill PDPRA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2019 · third_quarter · Q3
Medicare Part D Redesign, Drug Pricing (H.R.3, SFC bill PDPRA)
Medicare Part D, 42 CFR Part 2 (CONFIDENTIALITY OF SUBSTANCE USE DISORDER PATIENT RECORDS) Polycystic Kidney Disease,Mental Health
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2019 · second_quarter · Q2
Mental Health, 42 CFR Part 2 (CONFIDENTIALITY OF SUBSTANCE USE DISORDER PATIENT RECORDS) Polycystic Kidney Disease, Mental Health
Part D Rule - Medicare's 6 Protected Classes
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2019 · first_quarter · Q1
Medicare's 6 Protected Classes
Mental Health, 42 CFR Part 2 (CONFIDENTIALITY OF SUBSTANCE USE DISORDER PATIENT RECORDS) and HIPAA (Health Insurance Portability and Accountability Act of 1996), Polycystic Kidney Disease, Digital Medicine
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2018 · third_quarter · Q3
PKD (Polycystic Kidney Disease) Awareness, Opioid Package, S. 1850 (Protecting Jessica Grubb's Legacy Act), H.R. 3545 (Overdose Prevention and Patient Safety Act) and Veteran Affairs Issues
Opioid Package
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2018 · second_quarter · Q2
ADPKD (Autosomal dominant polycystic kidney disease); H.R.6082 OVERDOSE PREVENTION AND PATIENT SAFETY ACT - 42 CFR Part 2 - Federal confidentiality law and regulations; Health Care issuses as it relates to TBI (Traumatic Brain Injuries) Clinical Trials
Medical Innovation
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Nuclear Regulatory Commission (NRC), SENATE, Veterans Affairs, Dept of (VA)
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2018 · first_quarter · 1A
Health care, Digital Health, Mental Health and the value of the MyCite product, Autosomal dominant polycystic kidney disease (ADPKD) education,
Budget Bill which included Medicare donut hole prevision
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2018 · first_quarter · 1A
Health care, Digital Health, Mental Health and the value of the MyCite product, Autosomal dominant polycystic kidney disease (ADPKD) education,
Budget Bill which included Medicare donut hole prevision
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2018 · first_quarter · Q1
Budget Bill which included Medicare donut hole prevision
Health care, Digital Health, Mental Health and the value of the MyCite product, Autosomal dominant polycystic kidney disease (ADPKD) education,
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)